Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Perez EA
Predictors of Survival Following Emergent Surgical Decompression for Acutely Presenting Spinal Metastasis
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Protein kinase D1 regulates subcellular localisation and metastatic function of metastasis-associated protein 1
Cancer progression and metastasis is profoundly influenced by protein kinase D1 (PKD1) and metastasis-associated protein 1 (MTA1) in addition to other pathways. However, the nature of regulatory relationship between the PKD1 and MTA1, and its resulting impact on cancer metastasis remains unknown. Here we present evidence to establish that PKD1 is an upstream regulatory kinase of MTA1.
Protein kinase D1: gatekeeper of the epithelial phenotype and key regulator of cancer metastasis?
The development of epithelial cancer and subsequent metastasis goes along with loss of cellular polarity and cell–cell connections (Gandalovicova et al, 2016). Epithelial-to-mesenchymal transition (EMT) and reorganisation of the extracellular matrix by secreted matrix metalloproteinases (MMPs) are key mechanisms in the separation of tumour cells from the surrounding cells, and their dissemination to distant locations in the body (Nistico et al, 2012).
Immune gene expression and response to chemotherapy in advanced breast cancer
Transcriptomic profiles have shown promise as predictors of response to neoadjuvant chemotherapy in breast cancer (BC). This study aimed to explore their predictive value in the advanced BC (ABC) setting. In a Phase 3 trial of first-line chemotherapy in ABC, a fine needle aspiration biopsy (FNAB) was obtained at baseline.
Drugs That May Cause or Exacerbate Heart Failure
Introduction Heart failure (HF) remains the leading discharge diagnosis among patients ≥65 years of age. The estimated cost for treatment of HF in Medicare recipients is $31 billion and is expected to increase to $53 billion by 2030.1 Hospitalization for HF is the largest segment of those costs. It is likely that the prevention of drug-drug interactions and direct myocardial toxicity would reduce hospital admissions, thus both reducing costs and improving quality of life.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Perez
Contact Perez, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack